GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
GO:00066412 | Liver | HCC | triglyceride metabolic process | 59/7958 | 100/18723 | 6.35e-04 | 3.93e-03 | 59 |
GO:000663911 | Liver | HCC | acylglycerol metabolic process | 72/7958 | 128/18723 | 1.16e-03 | 6.54e-03 | 72 |
GO:0006654 | Liver | HCC | phosphatidic acid biosynthetic process | 23/7958 | 33/18723 | 1.46e-03 | 7.75e-03 | 23 |
GO:000663811 | Liver | HCC | neutral lipid metabolic process | 72/7958 | 129/18723 | 1.54e-03 | 8.14e-03 | 72 |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
GO:00464732 | Liver | HCC | phosphatidic acid metabolic process | 24/7958 | 37/18723 | 5.03e-03 | 2.11e-02 | 24 |
GO:0046341 | Liver | HCC | CDP-diacylglycerol metabolic process | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
GO:00194321 | Liver | HCC | triglyceride biosynthetic process | 26/7958 | 42/18723 | 8.76e-03 | 3.41e-02 | 26 |
GO:003526421 | Liver | HCC | multicellular organism growth | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
GO:0052646 | Liver | HCC | alditol phosphate metabolic process | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
GO:0016024 | Liver | HCC | CDP-diacylglycerol biosynthetic process | 10/7958 | 13/18723 | 1.28e-02 | 4.61e-02 | 10 |
GO:004592711 | Liver | HCC | positive regulation of growth | 128/7958 | 259/18723 | 1.41e-02 | 4.99e-02 | 128 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPAM | SNV | Missense_Mutation | | c.431N>A | p.Ala144Glu | p.A144E | Q9HCL2 | protein_coding | tolerated(0.69) | benign(0) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GPAM | SNV | Missense_Mutation | novel | c.2449N>C | p.Lys817Gln | p.K817Q | Q9HCL2 | protein_coding | deleterious(0.03) | benign(0.444) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GPAM | SNV | Missense_Mutation | novel | c.2105N>A | p.Arg702Gln | p.R702Q | Q9HCL2 | protein_coding | tolerated(0.18) | probably_damaging(0.968) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GPAM | SNV | Missense_Mutation | novel | c.2185C>G | p.Leu729Val | p.L729V | Q9HCL2 | protein_coding | tolerated(0.16) | probably_damaging(0.987) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
GPAM | SNV | Missense_Mutation | | c.2234N>A | p.Pro745His | p.P745H | Q9HCL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.641) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
GPAM | SNV | Missense_Mutation | rs776876225 | c.562C>A | p.Leu188Met | p.L188M | Q9HCL2 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-E2-A15I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GPAM | SNV | Missense_Mutation | novel | c.2201N>G | p.Ser734Cys | p.S734C | Q9HCL2 | protein_coding | deleterious(0.04) | benign(0.443) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
GPAM | insertion | Frame_Shift_Ins | novel | c.342_343insCAGACTGACTGGGTGGGTGCTGCTA | p.Ile115GlnfsTer16 | p.I115Qfs*16 | Q9HCL2 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GPAM | insertion | Frame_Shift_Ins | novel | c.340_341insGT | p.Phe114CysfsTer17 | p.F114Cfs*17 | Q9HCL2 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GPAM | insertion | In_Frame_Ins | novel | c.2419_2420insCTCTGAAAATGCATGAAAAACAAAGGCAAAAACTAG | p.Ser807delinsThrLeuLysMetHisGluLysGlnArgGlnLysLeuGly | p.S807delinsTLKMHEKQRQKLG | Q9HCL2 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |